Work

Effect of CYP3A4 Genetic Polymorphism on Clinical Response of Tamoxifen in Postmenopausal Iraqi Women with Breast Cancer

Year: 2025

Type: article

Abstract: Breast cancer is the leading cause of death and is the most frequent disease among women. Tamoxifen is an antiestrogen used to treat breast cancer. It may completely halt the disease's progression in high-risk individuals and lower the risk of death and recurrence in premenopausal and postmenopausal women. Variations in tamoxifen responsiveness between individuals may be attributed to polymorphisms in the primary metabolizing enzyme CYP3A4. The wild genotype (GG) of rs35599367 was found to be most common in 100 female breast cancer patients who were hormone receptor positive and taking tamoxifen, according to the study. This genetic variation may have a significant impact, as the GG genotype is strongly linked to significantly lower levels of CA15.3 and estrogen. Therefore, the results of this study imply that CYP3A4 variations may be a useful predictor of a patient's prognosis and response to tamoxifen. Keywords: CA 15.3, CYP3A4 polymorphism, Estradiol, Tamoxifen.

Source: Iraqi Journal of Pharmaceutical Sciences

DOI: 10.31351/vol34iss4pp23-32

Authors: Arjwan Fouad Hussain, Shaima Jabbar, Amal Umran Mosa, Ahmed Salih Sahib, Jamal Ali Ashoor, Karrar Kadhim Mohsin

Institutions: University of Kerbala, Ahl Al Bayt University

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: University of Kerbala